CTDSP1; ALPI; TDP1; HSD17B1; AKR1B1; HSD17B2; ALOX15; NOX4; POLB; | |
GAA; | |
DAPK1; FLT3; | |
CA2; CA12; CA7; CA4; | |
AR; | |
ESRRA; | |
ALOX5; TYR; XDH; | |
AHR; HIF1A; TP53; | |
ABCG2; ABCC1; | |
LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.253E-12 | 1.635E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.788E-11 | 2.664E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.796E-10 | 3.555E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.651E-10 | 3.555E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.358E-09 | 1.071E-05 | CA12, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0020037; heme binding | 5.921E-08 | 5.157E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.232E-08 | 6.639E-05 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.520E-07 | 2.129E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 4.586E-07 | 2.628E-04 | AKR1B1, AR, CYP1A1, CYP1A2, CYP1B1, DAPK1, ESRRA, HSD17B2, NOX4, POLB, TP53, TYR |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.037E-07 | 4.352E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.994E-07 | 4.352E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.754E-06 | 8.304E-04 | AR, CA2, CYP1A1, CYP1A2, ESRRA, FLT3, HSD17B2, TP53, TYR |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.383E-06 | 2.170E-03 | CYP1A1, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.151E-06 | 2.671E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.151E-06 | 2.671E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.968E-06 | 2.822E-03 | CA2, CA7 |
BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 8.036E-06 | 2.822E-03 | CYP1B1, HIF1A, NOX4, TP53, XDH |
BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.221E-05 | 3.969E-03 | ALOX15, CA2, CYP1A1, CYP1A2, HIF1A, TP53 |
BP | GO:0009987; cellular process | GO:0034599; cellular response to oxidative stress | 1.568E-05 | 4.622E-03 | AKR1B1, CYP1B1, DAPK1, NOX4, TP53 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.592E-05 | 4.622E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.592E-05 | 4.622E-03 | CYP1A2, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.799E-05 | 5.087E-03 | ABCC1, ALOX15, ALOX5 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 2.037E-05 | 5.614E-03 | ABCC1, AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.387E-05 | 6.416E-03 | CYP1A1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.946E-05 | 7.636E-03 | AKR1B1, CYP1A2, NOX4, XDH |
BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 3.809E-05 | 9.758E-03 | AHR, AKR1B1, AR, CYP1B1, ESRRA, FLT3, HIF1A, LMNA, NOX4, TP53, XDH |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 3.972E-05 | 9.972E-03 | ALOX15, ALOX5 |
BP | GO:0009987; cellular process | GO:0010647; positive regulation of cell communication | 4.076E-05 | 9.972E-03 | AKR1B1, ALOX15, AR, CA2, CA7, CYP1B1, FLT3, HIF1A, NOX4, TP53, XDH |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.069E-05 | 9.972E-03 | ALPI, AR, CA12, CA2, CA4, CA7, ESRRA, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.522E-08 | 5.758E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.133E-08 | 5.758E-07 | GAA; ALOX15; AKR1B1; CYP2C19; TYR; CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; ALPI; XDH |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.261E-08 | 6.604E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.266E-08 | 5.758E-07 | CA12; CA2; CA4; CA7 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.890E-07 | 2.552E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.246E-07 | 2.019E-06 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.820E-06 | 3.264E-05 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.436E-06 | 5.504E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.969E-05 | 2.405E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.531E-05 | 2.600E-04 | CYP1A2; CYP1A1; CYP1B1 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.891E-04 | 2.101E-03 | AR; FLT3; DAPK1; HIF1A; TP53 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.663E-04 | 1.036E-03 | FLT3; TP53; HIF1A |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.519E-04 | 1.025E-03 | CYP2C9; CYP1A2; CYP1A1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.814E-04 | 1.050E-03 | CYP2C9; CYP1A2; CYP2C19 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.956E-03 | 8.802E-03 | DAPK1; TP53 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.905E-03 | 3.435E-02 | AR; TP53 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.170E-02 | 4.307E-02 | ABCC1; CYP1B1; TP53 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.753E-03 | 2.330E-02 | CA2; ABCG2 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.250E-03 | 9.591E-03 | ABCC1; ABCG2 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.049E-03 | 4.999E-03 | GAA; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.144E-04 | 3.111E-03 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.473E-05 | 2.225E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
NA: NA | HIV infections | NA | AHR |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; FLT3; FLT3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; ESRRA |
C00-D49: Neoplasms | Bladder cancer | C67 | AR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3 |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
C00-D49: Neoplasms | CLL | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
C00-D49: Neoplasms | AML | NA | FLT3 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Melanoma | C43 | TYR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
NA: NA | Male hypogonadism | NA | AR |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ESRRA |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |